Dynavax Technologies Corporation

DVAX

NASDAQBiotechnology🇺🇸North America

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

May 29, 2026

Drug Pipeline

Drug Name	Phase	Indication	Designations
Fendrix	Phase 3	End Stage Renal Disease	-
HEPLISAV and/or Placebo	Phase 3	Healthy	-
HEPLISAV-B	Phase 3	Chronic Kidney Disease	-
Engerix-B	Phase 3	Hepatitis B	-
HEPLISAV	Phase 2	Hepatitis B	-
Amb a 1 Immunostimulatory Oligoribonucleotide Conjugate	Phase 2	Rhinitis, Allergic, Seasonal	-
rF1V-1018	Phase 2	Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersenia Pestis	-
Z-1018	Phase 2	Shingles	-
rF1V vaccine	Phase 2	Plague, Pneumonic	-

Catalyst Timeline

1 upcoming, 0 past

Phase 2Next

May 29, 2026rF1V-1018

Primary completion for rF1V-1018 trial (NCT07207408) in Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersenia Pestis

Regulatory Approvals

DVAX News